Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine

• Main Authors: Mohsen, Mona O., Vogel, Monique, Riether, Carsten, Muller, Julius, Salatino, Silvia, Ternette, Nicola, Gomes, Ariane C., Cabral-Miranda, Gustavo, El-Turabi, Aadil, Ruedl, Christiane, Kundig, Thomas M., Dermime, Said, Knuth, Alexander, Speiser, Daniel E., Bachmann, Martin F.
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2019
• Subjects: Virus-like Particles; Vaccine; DRNTU::Science::Biological sciences
• Online Access: https://hdl.handle.net/10356/104713; http://hdl.handle.net/10220/48630
• Institution: Nanyang Technological University

Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...